Trexquant Investment LP Bei Gene, Ltd. Transaction History

Trexquant Investment LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$158.67 - $201.58 $966,300 - $1.23 Million	6,090 New	6,090 $1.1 Million
Q1 2023 May 15, 2023	BUY	$215.53 - $274.5 $374,160 - $476,532	1,736 New	1,736 $374,000
Q2 2022 Aug 11, 2022	BUY	$121.11 - $216.05 $203,707 - $363,396	1,682 New	1,682 $272,000
Q3 2021 Nov 12, 2021	SELL	$249.6 - $403.14 $507,436 - $819,583	-2,033 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$292.75 - $367.01 $595,160 - $746,131	2,033 New	2,033 $698,000
Q2 2020 Aug 07, 2020	SELL	$123.9 - $195.41 $377,895 - $596,000	-3,050 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$121.84 - $173.19 $371,612 - $528,229	3,050 New	3,050 $375,000
Q3 2019 Nov 08, 2019	SELL	$120.61 - $148.29 $1.12 Million - $1.37 Million	-9,248 Closed	0 $0
Q2 2019 Aug 09, 2019	BUY	$113.99 - $146.86 $521,732 - $672,178	4,577 Added 97.99%	9,248 $1.15 Million
Q1 2019 May 13, 2019	BUY	$122.82 - $151.83 $573,692 - $709,197	4,671 New	4,671 $617,000

253

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $22.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.